ARS Pharmaceuticals, Inc.
NASDAQ: SPRY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard E. Lowenthal
- Employees
- 155
- Headquarters
- San Diego, United States
- IPO year
- 2020
- Market cap
- $1.0B
- Website
- https://ars-pharma.com
Loading SPRY…
Loading profile data…Frequently asked questions about SPRY
What does ARS Pharmaceuticals, Inc. (SPRY) do?
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its of...
Where does SPRY trade?
ARS Pharmaceuticals, Inc. (SPRY) trades on the NASDAQ Global Market.
What sector is SPRY in?
ARS Pharmaceuticals, Inc. (SPRY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ARS Pharmaceuticals, Inc.?
Richard E. Lowenthal is the chief executive officer of ARS Pharmaceuticals, Inc. (SPRY).
Where is ARS Pharmaceuticals, Inc. headquartered?
ARS Pharmaceuticals, Inc. is headquartered in United States.
Does SPRY pay a dividend?
ARS Pharmaceuticals, Inc. (SPRY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SPRY go public?
ARS Pharmaceuticals, Inc. (SPRY) completed its initial public offering in 2020.